220 related articles for article (PubMed ID: 25485910)
1. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance.
Yoda A; Adelmant G; Tamburini J; Chapuy B; Shindoh N; Yoda Y; Weigert O; Kopp N; Wu SC; Kim SS; Liu H; Tivey T; Christie AL; Elpek KG; Card J; Gritsman K; Gotlib J; Deininger MW; Makishima H; Turley SJ; Javidi-Sharifi N; Maciejewski JP; Jaiswal S; Ebert BL; Rodig SJ; Tyner JW; Marto JA; Weinstock DM; Lane AA
Nat Med; 2015 Jan; 21(1):71-5. PubMed ID: 25485910
[TBL] [Abstract][Full Text] [Related]
2. An activating mutation of GNB1 is associated with resistance to tyrosine kinase inhibitors in ETV6-ABL1-positive leukemia.
Zimmermannova O; Doktorova E; Stuchly J; Kanderova V; Kuzilkova D; Strnad H; Starkova J; Alberich-Jorda M; Falkenburg JHF; Trka J; Petrak J; Zuna J; Zaliova M
Oncogene; 2017 Oct; 36(43):5985-5994. PubMed ID: 28650474
[TBL] [Abstract][Full Text] [Related]
3. Oncogenes: nothing but a G thing.
Danovi S
Nat Rev Cancer; 2015 Feb; 15(2):68. PubMed ID: 25614000
[No Abstract] [Full Text] [Related]
4. Targeting PIM kinases impairs survival of hematopoietic cells transformed by kinase inhibitor-sensitive and kinase inhibitor-resistant forms of Fms-like tyrosine kinase 3 and BCR/ABL.
Adam M; Pogacic V; Bendit M; Chappuis R; Nawijn MC; Duyster J; Fox CJ; Thompson CB; Cools J; Schwaller J
Cancer Res; 2006 Apr; 66(7):3828-35. PubMed ID: 16585210
[TBL] [Abstract][Full Text] [Related]
5. G2A is an oncogenic G protein-coupled receptor.
Zohn IE; Klinger M; Karp X; Kirk H; Symons M; Chrzanowska-Wodnicka M; Der CJ; Kay RJ
Oncogene; 2000 Aug; 19(34):3866-77. PubMed ID: 10951580
[TBL] [Abstract][Full Text] [Related]
6. Transformation of hematopoietic cells by BCR/ABL requires activation of a PI-3k/Akt-dependent pathway.
Skorski T; Bellacosa A; Nieborowska-Skorska M; Majewski M; Martinez R; Choi JK; Trotta R; Wlodarski P; Perrotti D; Chan TO; Wasik MA; Tsichlis PN; Calabretta B
EMBO J; 1997 Oct; 16(20):6151-61. PubMed ID: 9321394
[TBL] [Abstract][Full Text] [Related]
7. Different target range and cytotoxic specificity of adaphostin and 17-allylamino-17-demethoxygeldanamycin in imatinib-resistant and sensitive cell lines.
Barnes DJ; De S; van Hensbergen P; Moravcsik E; Melo JV
Leukemia; 2007 Mar; 21(3):421-6. PubMed ID: 17252018
[TBL] [Abstract][Full Text] [Related]
8. Compensatory PI3-kinase/Akt/mTor activation regulates imatinib resistance development.
Burchert A; Wang Y; Cai D; von Bubnoff N; Paschka P; Müller-Brüsselbach S; Ottmann OG; Duyster J; Hochhaus A; Neubauer A
Leukemia; 2005 Oct; 19(10):1774-82. PubMed ID: 16136169
[TBL] [Abstract][Full Text] [Related]
9. Germline De Novo Mutations in GNB1 Cause Severe Neurodevelopmental Disability, Hypotonia, and Seizures.
Petrovski S; Küry S; Myers CT; Anyane-Yeboa K; Cogné B; Bialer M; Xia F; Hemati P; Riviello J; Mehaffey M; Besnard T; Becraft E; Wadley A; Politi AR; Colombo S; Zhu X; Ren Z; Andrews I; Dudding-Byth T; Schneider AL; Wallace G; ; Rosen ABI; Schelley S; Enns GM; Corre P; Dalton J; Mercier S; Latypova X; Schmitt S; Guzman E; Moore C; Bier L; Heinzen EL; Karachunski P; Shur N; Grebe T; Basinger A; Nguyen JM; Bézieau S; Wierenga K; Bernstein JA; Scheffer IE; Rosenfeld JA; Mefford HC; Isidor B; Goldstein DB
Am J Hum Genet; 2016 May; 98(5):1001-1010. PubMed ID: 27108799
[TBL] [Abstract][Full Text] [Related]
10. Novel GNB1 mutations disrupt assembly and function of G protein heterotrimers and cause global developmental delay in humans.
Lohmann K; Masuho I; Patil DN; Baumann H; Hebert E; Steinrücke S; Trujillano D; Skamangas NK; Dobricic V; Hüning I; Gillessen-Kaesbach G; Westenberger A; Savic-Pavicevic D; Münchau A; Oprea G; Klein C; Rolfs A; Martemyanov KA
Hum Mol Genet; 2017 Mar; 26(6):1078-1086. PubMed ID: 28087732
[TBL] [Abstract][Full Text] [Related]
11. Gab2 signaling in chronic myeloid leukemia cells confers resistance to multiple Bcr-Abl inhibitors.
Wöhrle FU; Halbach S; Aumann K; Schwemmers S; Braun S; Auberger P; Schramek D; Penninger JM; Laßmann S; Werner M; Waller CF; Pahl HL; Zeiser R; Daly RJ; Brummer T
Leukemia; 2013 Jan; 27(1):118-29. PubMed ID: 22858987
[TBL] [Abstract][Full Text] [Related]
12. Gβγ interacts with mTOR and promotes its activation.
Robles-Molina E; Dionisio-Vicuña M; Guzmán-Hernández ML; Reyes-Cruz G; Vázquez-Prado J
Biochem Biophys Res Commun; 2014 Feb; 444(2):218-23. PubMed ID: 24462769
[TBL] [Abstract][Full Text] [Related]
13. HS-438, a new inhibitor of imatinib-resistant BCR-ABL T315I mutation in chronic myeloid leukemia.
Yun SM; Jung KH; Kim SJ; Fang Z; Son MK; Yan HH; Lee H; Kim J; Shin S; Hong S; Hong SS
Cancer Lett; 2014 Jun; 348(1-2):50-60. PubMed ID: 24657654
[TBL] [Abstract][Full Text] [Related]
14. Pertussis toxin-sensitive Gi/o proteins are involved in nerve growth factor-induced pro-survival Akt signaling cascade in PC12 cells.
Wu EH; Wong YH
Cell Signal; 2005 Jul; 17(7):881-90. PubMed ID: 15763430
[TBL] [Abstract][Full Text] [Related]
15. Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S; Mologni L; Rostagno R; Piazza R; Magistroni V; Ceccon M; Viltadi M; Flynn D; Gambacorti-Passerini C
Am J Hematol; 2012 Nov; 87(11):E125-8. PubMed ID: 23044928
[TBL] [Abstract][Full Text] [Related]
16. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
17. Phosphorylation of the ATP-binding loop directs oncogenicity of drug-resistant BCR-ABL mutants.
Skaggs BJ; Gorre ME; Ryvkin A; Burgess MR; Xie Y; Han Y; Komisopoulou E; Brown LM; Loo JA; Landaw EM; Sawyers CL; Graeber TG
Proc Natl Acad Sci U S A; 2006 Dec; 103(51):19466-71. PubMed ID: 17164333
[TBL] [Abstract][Full Text] [Related]
18. Structural mechanism of the Pan-BCR-ABL inhibitor ponatinib (AP24534): lessons for overcoming kinase inhibitor resistance.
Zhou T; Commodore L; Huang WS; Wang Y; Thomas M; Keats J; Xu Q; Rivera VM; Shakespeare WC; Clackson T; Dalgarno DC; Zhu X
Chem Biol Drug Des; 2011 Jan; 77(1):1-11. PubMed ID: 21118377
[TBL] [Abstract][Full Text] [Related]
19. Role of the cAMP and MAPK pathways in the transformation of mouse 3T3 fibroblasts by a TSHR gene constitutively activated by point mutation.
Du Villard JA; Wicker R; Crespo P; Russo D; Filetti S; Gutkind JS; Sarasin A; Suárez HG
Oncogene; 2000 Oct; 19(42):4896-905. PubMed ID: 11039907
[TBL] [Abstract][Full Text] [Related]
20. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression.
Guerrero S; Casanova I; Farré L; Mazo A; Capellà G; Mangues R
Cancer Res; 2000 Dec; 60(23):6750-6. PubMed ID: 11118062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
